Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension
暂无分享,去创建一个
R. Eastell | S. Ralston | M. Brandi | R. Lachmann | Steven W. Ing | K. Briot | Hiroyuki Tanaka | M. Javaid | H. Yoo | Y. Takeuchi | Y. Imanishi | T. Kubota | M. Cohen-Solal | A. Nixon | T. Weber | R. Keen | P. Kamenickỷ | K. Insogna | T. Carpenter | R. Crowley | A. Portale | Farzana Perwad | P. Pitukcheewanont | E. Imel | H. I. Cheong | Wei Sun | S. Jan de Beur | N. Ito | M. Nixon | Angela Williams | M. Cohen‐Solal | A. Williams
[1] M. Rowbotham,et al. Interpretation of chronic pain clinical trial outcomes: IMMPACT recommended considerations. , 2020, Pain.
[2] E. Imel. Enthesopathy, Osteoarthritis, and Mobility in X-linked Hypophosphatemia , 2020, The Journal of clinical endocrinology and metabolism.
[3] A. Williams,et al. PRO80 PSYCHOMETRIC VALIDATION OF THE BRIEF FATIGUE INVENTORY (BFI) IN ADULT X-LINKED HYPOPHOSPHATEMIA (XLH) , 2020 .
[4] R. Lachmann,et al. Exploring the burden of X-linked hypophosphatemia: a European multi-country qualitative study , 2020, Quality of Life Research.
[5] C. Cleeland. Brief Pain Inventory , 2020, Definitions.
[6] N. Shaw,et al. Exploring the Burden of X-Linked Hypophosphataemia: An Opportunistic Qualitative Study of Patient Statements Generated During a Technology Appraisal , 2019, Advances in Therapy.
[7] A. Williams,et al. PRO154 CONFIRMATORY PSYCHOMETRIC VALIDATION OF THE BRIEF PAIN INVENTORY (BPI-SF) IN ADULT X-LINKED HYPOPHOSPHATEMIA (XLH) , 2019, Value in Health.
[8] A. Williams,et al. PRO152 CONFIRMATORY PSYCHOMETRIC VALIDATION OF THE WESTERN ONTARIO MCMASTER UNIVERSITIES OSTEOARTHRITIS INVENTORY (WOMAC) IN ADULT X-LINKED HYPOPHOSPHATEMIA (XLH) , 2019, Value in Health.
[9] J. Block,et al. Osteoarthritis is as severe as rheumatoid arthritis: evidence over 40 years according to the same measure in each disease. , 2019, Clinical and experimental rheumatology.
[10] R. Eastell,et al. Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period , 2019, Calcified Tissue International.
[11] L. Rejnmark,et al. Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia , 2019, Nature Reviews Nephrology.
[12] J. S. San Martin,et al. The Lifelong Impact of X-Linked Hypophosphatemia: Results From a Burden of Disease Survey , 2019, Journal of the Endocrine Society.
[13] J. S. San Martin,et al. A Randomized, Double‐Blind, Placebo‐Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti‐FGF23 Antibody, in Adults With X‐Linked Hypophosphatemia: Week 24 Primary Analysis , 2018, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[14] R. Arbuckle,et al. Qualitative Research to Explore the Patient Experience of X-Linked Hypophosphatemia and Evaluate the Suitability of the BPI-SF and WOMAC® as Clinical Trial End Points. , 2018, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[15] Viraj Ramesh Suvarna,et al. Real world evidence (RWE) - Are we (RWE) ready? , 2018, Perspectives in clinical research.
[16] C. Cooper,et al. Health-related quality of life and a cost-utility simulation of adults in the UK with osteogenesis imperfecta, X-linked hypophosphatemia and fibrous dysplasia , 2016, Orphanet Journal of Rare Diseases.
[17] C. Roux,et al. Impaired quality of life in adults with X-linked hypophosphatemia and skeletal symptoms. , 2016, European journal of endocrinology.
[18] P. Wicart,et al. Therapeutic management of hypophosphatemic rickets from infancy to adulthood , 2014, Endocrine connections.
[19] S. Acaster,et al. Methods for interpreting change over time in patient-reported outcome measures , 2013, Quality of Life Research.
[20] C. Cleeland. The Brief Pain Inventory User Guide , 2009 .
[21] David Cella,et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. , 2008, The journal of pain : official journal of the American Pain Society.
[22] S. Fukumoto,et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. , 2003, The New England journal of medicine.
[23] ATS Statement , 2002 .
[24] ATS statement: guidelines for the six-minute walk test. , 2002, American journal of respiratory and critical care medicine.
[25] W. Gibbons,et al. Reference values for a multiple repetition 6-minute walk test in healthy adults older than 20 years. , 2001, Journal of cardiopulmonary rehabilitation.
[26] C. Cleeland,et al. The rapid assessment of fatigue severity in cancer patients , 1999, Cancer.
[27] A. Poustka,et al. A gene (PEX) with homologies to endopeptidases is mutated in patients with X–linked hypophosphatemic rickets , 1995, Nature Genetics.
[28] W. A. Murphy,et al. X‐Linked Hypophosphatemia: A Clinical, Biochemical, and Histopathologic Assessment of Morbidity in Adults , 1989, Medicine.
[29] W. Murphy,et al. X-linked hypophosphatemia in adults: prevalence of skeletal radiographic and scintigraphic features. , 1989, Radiology.